Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest Galena Biopharma Stories

2014-04-16 20:22:56

SAN FRANCISCO, April 16, 2014 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP an investor-rights law firm with offices in San Francisco has intensified its investigation on behalf of Galena Biopharma, Inc. (NASDAQ: GALE) ("Galena" or "the Company") in light of the May 5, 2014 deadline to file for lead plaintiff in the securities fraud cases against the company. Investors who purchased Galena stock between May 9, 2013 and March 17, 2014 (the "Class Period") can contact Hagens Berman...

2014-04-09 08:25:49

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, April 9, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts' notes regarding Allergan Inc. (NYSE: AGN), Accuray Incorporated (NASDAQ: ARAY), Cerus Corporation (NASDAQ: CERS), Galena Biopharma, Inc. (NASDAQ: GALE), and ZELTIQ Aesthetics, Inc. (NASDAQ: ZLTQ). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings...

2014-04-07 16:25:49

BERKELEY, Calif., April 7, 2014 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP reminds investors of the May 5, 2014 deadline to file for lead plaintiff in a securities fraud case against Galena Biopharma, Inc. (NASDAQ: GALE) ("Galena" or "the Company"). The Class Period has been extended to cover investors who bought stock between May 9, 2013 and March 17, 2014 (the "Class Period"). Investors who purchased Galena securities during the Class Period may contact Hagens Berman Partner...

2014-03-24 20:22:55

DUBLIN, March 25, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/czqbv2/investigation) has announced the addition of the "Investigation Report on China Trastuzumab Market, 2009-2018" [http://www.researchandmarkets.com/research/czqbv2/investigation ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Trastuzumab is a monoclonal antibody that interferes with the HER2/neu receptor. Its main...

2014-03-12 16:26:33

SAN DIEGO and LAKE OSWEGO, Ore., March 12, 2014 /PRNewswire/ -- Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Galena Biopharma, Inc. (NASDAQ: GALE) has filed a federal securities fraud class action complaint in the U.S. District Court for the District of Oregon. The complaint alleges that the company and certain of its officers and directors violated the Securities and Exchange Act of 1934 between November 6, 2013 and February 14, 2014 (the "Class...

2014-03-06 16:27:07

NEW YORK, March 6, 2014 /PRNewswire/ -- Bernstein Liebhard LLP today announced that a class action has been commenced in the United States District Court for the District of Oregon on behalf of purchasers (the "Class") of common stock of Galena Biopharma, Inc. ("Galena" or the "Company") (NASDAQ: GALE) during the period of November 6, 2013 and February 14, 2014 (the "Class Period"). http://photos.prnewswire.com/prnvar/20120202/MM47134LOGO The complaint charges Galena and certain of...

2014-02-27 12:27:11

WORCESTER, Mass. and TORONTO, Feb. 27, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced publication of studies examining potential biomarkers associated with overall survival in prostate cancer patients treated with its immunotherapeutic agent AE37. The retrospective study examined data from 29 patients immunized as part of a Phase I study. The immunotherapeutic agent AE37 is being developed by Antigen Express, Inc....

2014-02-12 12:30:03

WORCESTER, Mass. and TORONTO, Feb. 12, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (GNBT) today announced that recent results from a Phase II study of a novel cancer vaccine designed to prevent relapse in patients who have had breast cancer corroborate prior results from an interim analysis conducted in October of 2011. The Company plans to disclose full results from the Phase II clinical trial at this year's American Society of Clinical Oncology (ASCO)...

2014-01-06 08:27:53

WORCESTER, Mass. and TORONTO, Jan. 6, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced the database lock for the primary efficacy analysis of its ongoing AE37 breast cancer vaccine trial. The drug is a novel immunotherapeutic cancer vaccine being developed by the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com). A previously released positive interim analysis showed a strong trend toward reduced...

2013-12-11 12:05:10

Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab, according to results presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14. "We have previously shown that high levels of tumor-infiltrating lymphocytes [immune cells in a tumor] are predictive of response to trastuzumab and chemotherapy administered after surgery for early-stage,...